Shahriar Shahir Barzegar, Founder of hoopoe holding, has announced the launch of a structured clinical framework for GLP-1 therapy delivery across the UAE, as part of the ongoing “Hayat Initiative” campaign. The announcement comes amid a sharp increase in demand for obesity and metabolic treatments, including injectable therapies such as Mounjaro by Eli Lilly and the anticipated entry of oral GLP-1 alternatives into the regional market. The newly introduced framework will be implemented across hoopoe holding’s clinical ecosystem, including elegant hoopoe polyclinic, and is designed to standardise how GLP-1 therapies are prescribed, monitored, and integrated into long-term metabolic care pathways. “The market is moving quickly toward broader access,” said Barzegar.…